Infographic: CRISPR editing for treating Duchenne muscular dystrophy

Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.

Natalya Ortolano, PhD Headshot
Oct 13, 2021
Natalya Ortolano, PhD

Natalya received her PhD in from Vanderbilt University in 2021; she joined the DDN team the same week she defended her thesis. Her work has been featured at STAT News,...

View full profile.


Learn about our editorial policies.

Duchenne muscular dystrophy is a rare genetic disorder that causes muscles to slowly break down over time, leading to symptoms such as difficulty walking. Dysfunction of the muscle stabilizing protein dystrophin is the primary cause of the disease. The biotech company MyoGeneBio uses CRISPR gene editing to restore partial function of dystrophin to minimize symptoms and slow the progression of disease.

Download the infographic: CRISPR editing for treating Duchenne muscular dystrophy

By Natalya Ortolano, PhD
illustrated by Shannon herring
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN June 2022 magazine issue front cover

Latest Issue  

• Volume 18 • Issue 6 • June 2022

June 2022

June 2022 Issue